IL10 and B-cell chronic lymphocytic leukemia: IL10-signaling in resting CLL cells is mediated by Janus kinases (JAKs) and can be blocked completely by the JAK-inhibitor Ruxolitinib (Li et al., 2015) and partially by IL10-blocking antibodies at 10 ng/ml in the presence or absence of LDLs (Supplementary Fig. 3).